Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer
- Registration Number
- NCT00525590
- Lead Sponsor
- Eisai Inc.
- Brief Summary
The purpose of this study is to determine the effect of the surgical intervention and insertion of GLIADEL wafers on the neurocognitive functioning in patients with metastatic brain cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 69
-
Can provide signed/dated Informed Consent, and Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization.
-
Are a male or female patient 18 years of age or older.
-
Are willing to a use barrier method of contraception if fertile or of childbearing potential until 30 days after surgical resection. If the patient receives subsequent chemotherapy during study participation (as allowed by the protocol), appropriate contraception will be managed by the principal investigator.
-
Have a primary diagnosis of solid-based tumor cancer (except small cell lung cancer (SCLS), lymphoma, germ cell cancer or anaplastic thyroid cancer) or unknown primary cancer and have 1-3 brain metastasis(es) for which surgical resection is planned for a single metastasis and any remaining metastases are planned for stereotactic radiosurgery (SRS);
OR
an intra-operative diagnosis of metastatic brain tumor in a patient with a single brain lesion.
-
Have a life expectancy of ≥12 weeks.
-
Have a Karnofsky Performance Status (KPS) score of 70 or higher.
-
Have Recursive Partitioning Analysis (RPA) status of 1 or 2.
-
Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of the surgical resection; and
-
Patients must be able to understand English, either orally or in writing, and be able to consent and complete the required assessments and procedures.
- Are unable or unwilling to understand study assessment or to cooperate with the study procedures as determined by the investigator.
- Have a history of allergic reaction or known hypersensitivity to BCNU (carmustine) or other components of the GLIADEL, such as polifeprosan polymer.
- Have a history of prior cranial irradiation.
- Have a prior diagnosis of Central Nervous System (CNS) tumor.
- Have received prior treatment for brain tumors.
- Have had prior exposure to GLIADEL or its components, such as polifeprosan polymer.
- Have any uncontrolled medical or psychiatric conditions which preclude them from participating in or completing the study procedures.
- Concurrent severe medical conditions include, but are not limited to, active infection, acute hepatitis, cardiac arrhythmia, unstable angina, congestive heart failure, uncontrolled diabetes mellitus, uncontrolled seizures, pulmonary insufficiency, pulmonary fibrosis, pulmonary embolus, etc.
- Have a diagnosis of tumor in the brain stem or posterior fossa.
- Have an RPA status of 3.
- Have a diagnosis of leptomeningeal disease at time of enrollment; or
- Are currently pregnant or lactating, or plan to become pregnant during the course of the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 GLIADEL -
- Primary Outcome Measures
Name Time Method Number of Participants With Neurocognitive Domains Preserved at Month 9 Month 9 Preservation of NF was defined as a decrease of \<=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain).
Number of Participants With Neurocognitive Domains Preserved at Month 12 Month 12 Preservation of NF was defined as a decrease of less than or equal to (\<=) 1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain).
Rate of Deterioration in Neurocognitive Functioning (NF) at Month 12 Month 12 NF was assessed as the performance of 3 neurocognitive domains:memory(MD),executive function(EFD), fine motor coordination(FMCD). For each domain, z-scores were derived from participant's scores in individual neurocognitive tests using an age-adjusted and education-adjusted normative distribution of scores from an unimpaired population.Individual z-scores from related tests were averaged to determine overall z-score.If a z-score average decreased from baseline by greater than or equal to(\>=)3 standard deviations(SD)in tests' normative age-adjusted distribution on 2 consecutive visits or decreased by \>=3 SD on last follow-up visit, participant were considered to have significant deterioration in their NF at time of the first decrease in z-score.Deterioration in NF:demonstrated deterioration for at least two of the three neurocognitive domains based on these changes from screening.Rate of deterioration in NF was measured as estimated percentage of participants using Kaplan-Meier method.
Number of Participants With Neurocognitive Domains Preserved at Month 2 Month 2 Preservation of NF was defined as a decrease of \<=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain).
Number of Participants With Neurocognitive Domains Preserved at Month 4 Month 4 Preservation of NF was defined as a decrease of \<=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain).
Number of Participants With Neurocognitive Domains Preserved at Month 6 Month 6 Preservation of NF was defined as a decrease of \<=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain).
- Secondary Outcome Measures
Name Time Method Correlation of Tumor Recurrence With Residual Mass Effect Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed) Percentage of Participants With Brain Tumor Recurrence (Local Recurrence, Distant Recurrence and Overall Recurrence) Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed) Time to Recurrence (Local, Distant and Overall) Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed) Percentage of Participants With Neurocognitive Decline in NF by Severity (Memory Domain, Executive Function Domain, and Fine Motor Coordination Domain) Months 2, 4, 6, 9 and 12 Neurocognitive decline was defined as any decrease in NF scores less than (\<) 0 SD from baseline. Here, in category titles EFD represents Executive Function Domain and FMCD represents Fine Motor Coordination Domain.
Percentage of Participants With Neurologic Death Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed) Neurologic Death was defined as death due to progression of neurologic disease.
Time to Neurocognitive Deterioration Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed) The time to neurocognitive deterioration was defined as the number of days between the date of study treatment and the date of neurocognitive deterioration based on NF assessment. This was assessed using Kaplan Meier method.
Correlation of Tumor Recurrence (Local, Distant or Overall) With NF Domain Scores Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed) The correlation between recurrence (local, distant or overall) \& NF was assessed by presenting change in NF domain scores (memory domain \[MD\], executive function domain \[EFD\], fine motor coordination domain \[FMCD\]) after tumor recurrence (Visits X, X+1, X+2, and X+3) compared to before tumor recurrence (Visit X-1). Here 'Visit X' refers to visit at which participants had tumor recurrence, Visit X-1 refers to visit immediately before the recurrence and X+1, X+2, X+3 refers to subsequent first, second \& third visit after the recurrence.NF domain z-scores were derived from participant's scores in individual neurocognitive tests using an age-adjusted \&education-adjusted normative distribution of scores from an unimpaired population. Individual z-scores from related tests were averaged to determine overall z-score for each of NF domains.
Trial Locations
- Locations (17)
University of Arizona / University Medical Center
🇺🇸Tucson, Arizona, United States
University of Iowa Hospitals and Clinics
🇺🇸Iowa City, Iowa, United States
Weill Medical College Department of Neurological Surgery
🇺🇸New York, New York, United States
Carolina Neurosurgery & Spine Associates
🇺🇸Charlotte, North Carolina, United States
Methodist University Hospital
🇺🇸Memphis, Tennessee, United States
Trinity Mother Frances Health System
🇺🇸Tyler, Texas, United States
The University of Chicago
🇺🇸Chicago, Illinois, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
The Ohio State University Medical Center
🇺🇸Columbus, Ohio, United States
Temple University
🇺🇸Philadelphia, Pennsylvania, United States
UT Southwestern Medical Center at Dallas
🇺🇸Dallas, Texas, United States
H. Lee Moffitt Cancer Center & Research Institute
🇺🇸Tampa, Florida, United States
University of California, Los Angeles
🇺🇸Los Angeles, California, United States
University of South Florida
🇺🇸Tampa, Florida, United States
NorthShore University HealthSystem Reseach Institute
🇺🇸Evanston, Illinois, United States
University of North Carolina
🇺🇸Chapel Hill, North Carolina, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States